Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth…
In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
asdfasdf
The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 600 currently available and novel biosimilar products, detailing…
The development and commercialization of biosimilars require a significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…
The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…
The development and commercialization of biosimilars require a significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…
The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…
The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…